Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

Katharina Schumann; Cornelia Mauch; Kai-Christian Klespe; Carmen Loquai; Ulrike Nikfarjam; Max Schlaak; Larissa Akçetin; Peter Kölblinger; Magdalena Hoellwerth; Wolfram Hötzenecker; Angela Öllinger; et al.

doi:10.1111/jdv.18779

Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

Katharina Schumann
, Cornelia Mauch
, Kai-Christian Klespe
, Carmen Loquai
, Ulrike Nikfarjam
, Max Schlaak
, Larissa Akçetin
, Peter Kölblinger
, Magdalena Hoellwerth
, Wolfram Hötzenecker
, Angela Öllinger
, et al.

Department of Dermatology and Venereology

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	894-906
Number of pages	13
Journal	Journal of the European Academy of Dermatology and Venerology
Volume	37
Issue number	5
DOIs	https://doi.org/10.1111/jdv.18779
Publication status	Published - May 2023

Fields of science

302087 Venereology
302011 Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jdv.18779

Cite this

Schumann, K., Mauch, C., Klespe, K.-C., Loquai, C., Nikfarjam, U., Schlaak, M., Akçetin, L., Kölblinger, P., Hoellwerth, M., Hötzenecker, W., Öllinger, A., & et al. (2023). Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. Journal of the European Academy of Dermatology and Venerology, 37(5), 894-906. https://doi.org/10.1111/jdv.18779

@article{82f1fa2c8a284dfca3ddc4dc30cc139c,

title = "Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland",

author = "Katharina Schumann and Cornelia Mauch and Kai-Christian Klespe and Carmen Loquai and Ulrike Nikfarjam and Max Schlaak and Larissa Ak{\c c}etin and Peter K{\"o}lblinger and Magdalena Hoellwerth and Wolfram H{\"o}tzenecker and Angela {\"O}llinger and \{et al.\}",

year = "2023",

month = may,

doi = "10.1111/jdv.18779",

language = "English",

volume = "37",

pages = "894--906",

journal = "Journal of the European Academy of Dermatology and Venerology",

issn = "0926-9959",

number = "5",

}

Schumann, K, Mauch, C, Klespe, K-C, Loquai, C, Nikfarjam, U, Schlaak, M, Akçetin, L, Kölblinger, P, Hoellwerth, M, Hötzenecker, W , Öllinger, A & et al. 2023, 'Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland', Journal of the European Academy of Dermatology and Venerology, vol. 37, no. 5, pp. 894-906. https://doi.org/10.1111/jdv.18779

Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. / Schumann, Katharina; Mauch, Cornelia; Klespe, Kai-Christian et al.
In: Journal of the European Academy of Dermatology and Venerology, Vol. 37, No. 5, 05.2023, p. 894-906.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

AU - Schumann, Katharina

AU - Mauch, Cornelia

AU - Klespe, Kai-Christian

AU - Loquai, Carmen

AU - Nikfarjam, Ulrike

AU - Schlaak, Max

AU - Akçetin, Larissa

AU - Kölblinger, Peter

AU - Hoellwerth, Magdalena

AU - Hötzenecker, Wolfram

AU - Öllinger, Angela

AU - et al., null

PY - 2023/5

Y1 - 2023/5

UR - https://www.scopus.com/pages/publications/85144079180

U2 - 10.1111/jdv.18779

DO - 10.1111/jdv.18779

M3 - Article

SN - 0926-9959

VL - 37

SP - 894

EP - 906

JO - Journal of the European Academy of Dermatology and Venerology

JF - Journal of the European Academy of Dermatology and Venerology

IS - 5

ER -

Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

Fields of science

UN SDGs

Access to Document

Other files and links

Cite this